(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.77%.
Ovid Therapeutics's earnings in 2026 is -$17,414,000.On average, 12 Wall Street analysts forecast OVID's earnings for 2026 to be -$61,414,017, with the lowest OVID earnings forecast at -$103,389,713, and the highest OVID earnings forecast at -$34,063,218. On average, 8 Wall Street analysts forecast OVID's earnings for 2027 to be -$72,122,237, with the lowest OVID earnings forecast at -$125,360,027, and the highest OVID earnings forecast at -$39,747,015.
In 2028, OVID is forecast to generate -$53,356,477 in earnings, with the lowest earnings forecast at -$64,618,571 and the highest earnings forecast at -$47,079,244.